Cargando…

The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors

The transcription factor Myeloid Ecotropic Insertion Site 2 (MEIS2) has been identified as a cellular substrate of the E3-ubiquitin ligase complex CRL4-cereblon ((CRL4)CRBN) in crystal structure and by biochemical screen. Emerging evidence suggests that IMiDs can block MEIS2 from binding to CRBN fac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abruzzese, Maria Pia, Bilotta, Maria Teresa, Fionda, Cinzia, Zingoni, Alessandra, Soriani, Alessandra, Petrucci, Maria Teresa, Ricciardi, Maria Rosaria, Molfetta, Rosa, Paolini, Rossella, Santoni, Angela, Cippitelli, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459881/ https://www.ncbi.nlm.nih.gov/pubmed/30975979 http://dx.doi.org/10.1038/s41419-019-1562-9

Ejemplares similares

The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma
por: Fionda, Cinzia, et al.
Publicado: (2015)

Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay
por: Abruzzese, Maria Pia, et al.
Publicado: (2016)

Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation
por: Fionda, Cinzia, et al.
Publicado: (2015)

IMiDs for myeloma induced renal impairment
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders
por: Jung, Yoo Jin, et al.
Publicado: (2021)

Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them
por: Cippitelli, Marco, et al.
Publicado: (2021)

NKG2D and Its Ligands: “One for All, All for One”
por: Zingoni, Alessandra, et al.
Publicado: (2018)

IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?
por: Suzuki, Kazuhito, et al.
Publicado: (2023)

A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders
por: Kopp, Katherine O., et al.
Publicado: (2023)

Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition
por: Petillo, Sara, et al.
Publicado: (2021)

NEDD8-activating enzyme inhibition potentiates the anti-myeloma activity of natural killer cells
por: Petillo, Sara, et al.
Publicado: (2023)

NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma
por: Fionda, Cinzia, et al.
Publicado: (2015)

Bone Marrow Stromal Cell-Derived IL-8 Upregulates PVR Expression on Multiple Myeloma Cells via NF-kB Transcription Factor
por: Mekhloufi, Abdelilah, et al.
Publicado: (2020)

Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs)
por: Liu, W M, et al.
Publicado: (2009)

Cereblon regulates NK cell cytotoxicity and migration via Rac1 activation
por: Fionda, Cinzia, et al.
Publicado: (2021)

Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance
por: Zingoni, Alessandra, et al.
Publicado: (2017)

Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma
por: Lien, I-Chia, et al.
Publicado: (2014)

Key Role of the CD56(low)CD16(low) Natural Killer Cell Subset in the Recognition and Killing of Multiple Myeloma Cells
por: Vulpis, Elisabetta, et al.
Publicado: (2018)

The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells
por: Cerboni, Cristina, et al.
Publicado: (2014)

IMiDs induce FAM83F degradation via an interaction with CK1α to attenuate Wnt signalling
por: Dunbar, Karen, et al.
Publicado: (2020)

GAS6/TAM signaling pathway controls MICA expression in multiple myeloma cells
por: Kosta, Andrea, et al.
Publicado: (2022)

Doxorubicin–Mediated miR–433 Expression on Exosomes Promotes Bystander Senescence in Multiple Myeloma Cells in a DDR–Independent Manner
por: Vulpis, Elisabetta, et al.
Publicado: (2023)

Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle‐associated MICA: Dual role in cancer immunosurveillance
por: Vulpis, Elisabetta, et al.
Publicado: (2022)

Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide
por: Bartlett, J B, et al.
Publicado: (2005)

Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide
por: Furihata, Hirotake, et al.
Publicado: (2020)

Effect of BET Missense Mutations on Bromodomain Function, Inhibitor Binding and Stability
por: Lori, Laura, et al.
Publicado: (2016)

IMiDs Augment CD3-Bispecific Antibody–Induced CD8(+) T-Cell Cytotoxicity and Expansion by Enhancing IL2 Production
por: Li, Ji, et al.
Publicado: (2023)

Selective inhibition of BET bromodomains
por: Filippakopoulos, Panagis, et al.
Publicado: (2010)

Cross-Dressing of Multiple Myeloma Cells Mediated by Extracellular Vesicles Conveying MIC and ULBP Ligands Promotes NK Cell Killing
por: Vulpis, Elisabetta, et al.
Publicado: (2023)

Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF
por: Corti, Angelo, et al.
Publicado: (2010)

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs
por: Herviou, Laurie, et al.
Publicado: (2018)

Post-translational Mechanisms Regulating NK Cell Activating Receptors and Their Ligands in Cancer: Potential Targets for Therapeutic Intervention
por: Molfetta, Rosa, et al.
Publicado: (2019)

Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent manner
por: Dimopoulos, Konstantinos, et al.
Publicado: (2017)

Discovery of Benzo[d]imidazole‐6‐sulfonamides as Bromodomain and Extra‐Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain
por: Cipriano, Alessandra, et al.
Publicado: (2022)

Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma
por: Soriani, Alessandra, et al.
Publicado: (2013)

Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition
por: Graziani, Vittoria, et al.
Publicado: (2023)

An IMiD-induced SALL4 degron system for selective degradation of target proteins
por: Yamanaka, Satoshi, et al.
Publicado: (2020)

309 MYC Inhibition Overcomes IMiD Resistance in Heterogeneous Multiple Myeloma Populations
por: Davis, Lorraine, et al.
Publicado: (2022)

A New Strategy for the Old Challenge of Thalidomide: Systems Biology Prioritization of Potential Immunomodulatory Drug (IMiD)-Targeted Transcription Factors
por: Kowalski, Thayne Woycinck, et al.
Publicado: (2023)

Targeting BET bromodomain proteins in solid tumors
por: Sahai, Vaibhav, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fi7kc9me13e4q8c79gsn4g392r